BioPharmX (BPMX) Misses Q4 EPS by 1c

BioPharmX (NYSE: BPMX) reported Q4 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $35 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on BioPharmX (BPMX) click here.

You May Also Be Interested In

• The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
• JPMorgan upgrades 3M, Emerson Electric to Overweight ahead of earnings
• Oppenheimer upgrades Ecolab to Outperform, sees AI growth driving upside